CRBP · Corbus Pharmaceuticals Holdings Inc
United States · RS rating 6 · As of 2026-11-03
| Price | 3.87 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 10 / 6 / 13 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 8 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +34.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +68.5% |
| Market cap (USD) | $181.3M |